Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HPGD | P15428 | 5/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.35 |
| ▸ | CTSG | P08311 | 2/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.35 |
| ▸ | KLK14 | Q9P0G3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860068 | 0.88 | TOP1 (0.43) | KDM4EALDH1A1HPGDATMGAA | |
| SCHEMBL6219000 | 0.85 | KDM4E (0.40) | KDM4EALDH1A1HPGDATMGAA | |
| Bromide SCHEMBL6431554 | 0.76 | KDM4E (0.48) | KDM4EALDH1A1HPGDATMGAA | |
| SCHEMBL5908880 | 0.70 | KDM4E (0.48) | KDM4EALDH1A1HPGDATMGAA | |
| SCHEMBL5859933 | 0.69 | KDM4E (0.43) | KDM4EALDH1A1HPGDHSD17B10TP53 | |
| SCHEMBL5860955 | 0.68 | ALDH1A1 (0.42) | KDM4EALDH1A1HPGDGAAMEN1 | |
| SCHEMBL5860177 | 0.68 | MAPT (0.44) | KDM4EALDH1A1HPGDGAAMEN1 | |
| SCHEMBL5861259 | 0.68 | ALDH1A1 (0.41) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL6220451 | 0.67 | PGK1 (0.41) | ALDH1A1ALOX15LMNASMN1; SMN2MAPT | |
| SCHEMBL5862670 | 0.67 | TNF (0.39) | KDM4EALDH1A1HPGDGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254908-B9 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARM INC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1254908-B1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARM INC (US) | 2005-02-23 | — | — | EP | disclosed |
| US-6821982-B2 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| EP-0758333-B1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | OSI PHARM INC (US) | 2004-03-03 | — | — | EP | disclosed |
| US-20030204088-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2003-10-30 | — | — | US | disclosed |
| US-6559309-B2 | Preparation for camptothecin and camptothecin-like compounds and to novel intermediates used in this preparation. The process for the preparation of the camptothecin derivative known by 7-(4 | OSI PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20030045719-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | OSI PHARMACEUTICALS, INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1254908-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | GILEAD SCIENCES, INC. (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-0758335-B1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GILEAD SCIENCES INC (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6462196-B1 | NOVEL INTERMEDIATES USED IN THE PREPARATION OF CAMPTOTHECIN DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6063923-A | Preparation of a camptothecin derivative by intramolecular cyclisation | GLAXO WELLCOME INC. (US) | 2000-05-16 | — | — | US | disclosed |
| EP-0758333-A1 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| EP-0758335-A1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GLAXO WELLCOME INC. (US) | 1997-02-19 | — | — | EP | disclosed |
| US-5491237-A | Intermediates in pharmaceutical camptothecin preparation | GLAXO WELLCOME INC. (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995029917-A2 | INTERMEDIATES IN PHARMACEUTICAL CAMPTOTHECIN PREPARATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995029919-A1 | PREPARATION OF A CAMPTOTHECIN DERIVATIVE BY INTRAMOLECULAR CYCLISATION | GLAXO WELLCOME INC. (US) | 1995-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030204088-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | TOP1, TOP2A, TOP2B | KDM4E 3990/4885ALDH1A1 1514/4885HPGD 608/4885 |
| US-20030045719-A1 | Preparation of a camptothecin derivative by intramolecular cyclisation | TOP1, TOP2A, TOP2B | KDM4E 4225/4885ALDH1A1 1456/4885HPGD 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.